Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy-Reference-Cited by-同舟云学术

Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy

Published:2021-04-06 Issue:1 Volume:4 Page:77-83
ISSN:2582-0370
Container-title:Asploro Journal of Biomedical and Clinical Case Reports
language:en
Short-container-title:Asp Biomed Clin Case Rep

Author:

H Bando¹^ORCID,Y Kato²,Y Kato²,S Matsuzaki²,S Waka²,K Ogura²

Affiliation:

1. Tokushima University/Medical Research, Tokushima, Japan; Kanaiso Hospital, Komatsushima, Tokushima, Japan

2. Kanaiso Hospital, Komatsushima, Tokushima, Japan

Abstract

The patient is a 56-year old (yo) female with type 2 diabetes mellitus (T2DM). Medical histories include persisting T2DM from 35yo, renal stone at 43yo, hypertension from 45yo, photocoagulation for retinopathy on 54yo. An incidentaloma was found in the left adrenal gland, where endocrinological exams were negative for functional tumor. Her diabetic control situation became worse with HbA1c > 10%, then the treatment has been changed from multiple daily injection (MDI), Dulaglutide to Xultophy which is combined agents of degludec and liraglutide (IDegLira). It was provided 10-18 doses daily, and then glucose variability profile was improved satisfactory, suggesting the dual synergistic effects.

Publisher

Asploro Open Access Publications

Reference30 articles.

1. International Diabetes Federation. Belgium: IDF Diabetes Atlas 9th edition; 2019. Available from: https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html

2. Smokovski I. Managing Diabetes in Low Income Countries: Providing Sustainable Diabetes Care with Limited Resources. Springer Nature; 2020.

3. Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besançon S, Bommer C, Esteghamati A, Ogurtsova K, Zhang P, Colagiuri S. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020 Apr;162:108072. [PMID: 32061820]

4. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S111-S24. [PMID: 33298420]

5. Yu M, Benjamin MM, Srinivasan S, Morin EE, Shishatskaya EI, Schwendeman SP, Schwendeman A. Battle of GLP-1 delivery technologies. Adv Drug Deliv Rev. 2018 May;130:113-30. [PMID: 30009885]